Palbociclib, Ribociclib and Abemaciclib in India 2026 — Which CDK4/6 Inhibitor Is Right for Your Patient?
Link Title
Link Short URL
Link Long URL
Description:
Breast cancer is now the most commonly diagnosed cancer among Indian women. Within that broad diagnosis, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer accounts for approximately 60-70% of all cases — and for this large and clinically important group, the treatment landscape has been fundamentally transformed over the past decade by a class of medicines called CDK4/6 inhibitors.
Read More…
Keywords (Tags):
Created by:
A.K Pharma | Pharmaceutical Distributors in Delhi
Created on:
Hits:
7
|